The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Shares of Exelixis EXEL were down 5.13% on Jan. 24, following a downgrade in rating by analysts at Oppenheimer. Oppenheimer ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- (ISIN Code: ES0167733015, ORY), a clinical-stage ...